Seres Therapeutics (MCRB) Operating Income: 2015-2025
Historic Operating Income for Seres Therapeutics (MCRB) over the last 11 years, with Sep 2025 value amounting to -$22.5 million.
- Seres Therapeutics' Operating Income rose 22.94% to -$22.5 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$103.4 million, marking a year-over-year increase of 20.13%. This contributed to the annual value of -$121.3 million for FY2024, which is 37.82% up from last year.
- Per Seres Therapeutics' latest filing, its Operating Income stood at -$22.5 million for Q3 2025, which was up 9.66% from -$24.9 million recorded in Q2 2025.
- In the past 5 years, Seres Therapeutics' Operating Income registered a high of $68.4 million during Q3 2021, and its lowest value of -$70.6 million during Q1 2023.
- Its 3-year average for Operating Income is -$27.1 million, with a median of -$28.9 million in 2024.
- Per our database at Business Quant, Seres Therapeutics' Operating Income skyrocketed by 328.06% in 2021 and then crashed by 2,038.88% in 2023.
- Over the past 5 years, Seres Therapeutics' Operating Income (Quarterly) stood at -$49.4 million in 2021, then soared by 96.50% to -$1.7 million in 2022, then crashed by 2,038.88% to -$37.0 million in 2023, then grew by 22.12% to -$28.8 million in 2024, then increased by 22.94% to -$22.5 million in 2025.
- Its Operating Income stands at -$22.5 million for Q3 2025, versus -$24.9 million for Q2 2025 and -$27.2 million for Q1 2025.